Compare
Vericel Corp vs Adaptive Biotechnologies Corp vs Iovance Biotherapeutics, Inc. vs Vaxart, Inc.
| Latest fiscal year | Vericel Corp VCEL | Adaptive Biotechnologies Corp ADPT | Iovance Biotherapeutics, Inc. IOVA | Vaxart, Inc. VXRT |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $276.26M | $276.98M | $263.50M | $237.26M |
| Revenue growth (YoY) | +16.5% | +54.8% | +60.6% | +726.7% |
| Gross margin | 74.4% (computed) | 74.2% (computed) | 34.3% (computed) | n/a |
| Operating margin | 4.0% | -20.6% | -153.1% | 7.6% |
| Net margin | 6.0% | -21.5% | -148.4% | 6.9% |
| Net income | $16.52M | -$59.50M | -$390.98M | $16.33M |
| EPS (Diluted) | $0.32 | -$0.39 | -$1.09 | $0.07 |
| Operating cash flow | $51.91M | -$45.99M | -$302.41M | $7.71M |
| Free cash flow | $24.75M | -$48.95M | -$336.24M | $7.57M |
| Cash & equivalents | $100.09M | $70.50M | $163.08M | n/a |
| Total assets | $487.97M | $512.74M | $913.17M | $186.08M |
| Total liabilities | $133.33M | $287.74M | $214.59M | $98.28M |
| Shareholders' equity | $354.64M | $218.79M | $698.58M | $87.80M |
| Return on year-end equity | 4.7% | -27.2% | -56.0% | 18.6% |
| Shares outstanding | 50.62M | 153.78M | 411.94M | 240.49M |
Revenue, most recent five fiscal years
| Fiscal year | Vericel Corp | Adaptive Biotechnologies Corp | Iovance Biotherapeutics, Inc. | Vaxart, Inc. |
|---|---|---|---|---|
| Latest | $276.26M Ended 2025-12-31 | $276.98M Ended 2025-12-31 | $263.50M Ended 2025-12-31 | $237.26M Ended 2025-12-31 |
| 1 year earlier | $237.22M Ended 2024-12-31 | $178.96M Ended 2024-12-31 | $164.07M Ended 2024-12-31 | $28.70M Ended 2024-12-31 |
| 2 years earlier | $197.52M Ended 2023-12-31 | $170.28M Ended 2023-12-31 | $1.19M Ended 2023-12-31 | $7.38M Ended 2023-12-31 |
| 3 years earlier | $163.70M Ended 2022-12-31 | $185.31M Ended 2022-12-31 | n/a | $107.0K Ended 2022-12-31 |
| 4 years earlier | $153.07M Ended 2021-12-31 | $154.34M Ended 2021-12-31 | n/a | $892.0K Ended 2021-12-31 |